Johnson & Johnson (JNJ)
Is Johnson & Johnson a Buy After Its Latest Earnings Report?
Many traded out of the pharmaceutical sector mainstay to leave it with a nearly 3% loss. While the company posted growth where it counts, the market seems to be expecting notable outperformance from large players in the industry these days.
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Johnson & Johnson's Spravato sales growth supports psychedelic drug opportunity: Jefferies
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression treatment, with Jefferies writing that the drug's commercial performance supports the long-term market opportunity for the sector. Johnson & Johnson (NYSE:JNJ) reported worldwide second-quarter Spravato (esketamine nasal spray) sales of $584 million, up 25% from the first quarter, including US sales of $514 million.
Why Johnson & Johnson's Earnings Dip Looks Like a Buying Opportunity
Johnson & Johnson NYSE: JNJ is an elite income investment because of its Dividend King status, healthy balance sheet, and incredibly strong, defensive business model. Critical details include its product portfolio and pipeline, which are producing numerous catalysts simultaneously in 2026.
Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is up 24.03% year to date and 65.92% over the past year, riding oncology strength and a raised full-year outlook.
J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue
The launch of artificial intelligence-powered imaging and mapping capabilities for electrophysiology, early momentum for a drug releasing system for bladder cancer treatment, and progress toward a table-integrated robotic surgical system are among the latest innovations from pharmaceuticals and MedTech company Johnson & Johnson.
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.
Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street
Johnson & Johnson delivered strong Q2 2026 results, with 6.6% annual revenue growth and robust performance across Pharma and MedTech divisions. JNJ maintains mid-to-high single digit revenue growth, a portfolio of 15+ "blockbuster" drugs, and a solid pipeline, supporting its blue-chip status. I am downgrading JNJ from Strong Buy to Buy due to valuation normalization and tempered forward share price expectations, despite continued operational strength.
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for the quarter, ahead of the Wall Street consensus estimate of $2.85.
JNJ Struggles for Direction Despite Notable Q2 Beat
Johnson & Johnson (NYSE:JNJ) is up 0.5% at $255.03 this morning, attempting to pivot higher and shed its early pre-market losses.
Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson Q2 Earnings Call Highlights
Johnson & Johnson NYSE: JNJ raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.
